Detail

Keywords

Clinical Medicine; Gynecology; Medical Oncology; Translational Medical Research

Research group(s)

• Translational Gynecology
  Head:
  Members:
  Thomas Bartl

Research interests

Find our workgroup's recent IJGC podcast, invited by Editor-in-Chief Dr. Pedro T. Ramirez on "ARID1A in NSMP Uterine Cancers" on podbean:

https://ijgcbmj.podbean.com/e/arid1a-in-nsmp-uterine-cancers-with-arina-onoprienko-and-thomas-bartl/

Grants

• A Novel Approach of Defining Therapeutic Targets in an Orphan Disease: Formalin-fixed paraffin-embedded Tumor Tissue and Ascites-derived Cell Pellets as a Promising Source for RNA-Profiling in Mucinous Ovarian Cancer (2021)
  Source of Funding: City of Vienna, Vienna Fund for Innovative Interdisciplinary Cancer Research
  Principal Investigator
• Molecular Characterisation of Novel Therapeutic Targets in Mucinius Ovarian Cancer (2019)
  Source of Funding: Medical Scientific Fund of the Mayor of the City of Vienna, Gynecologic Oncology
  Coordinator of the collaborative project
• Mucinous Ovarian Cancer in the Era of Personalized Medicine: Definition of Novel Biomarkers Predictive of Therapy Response (2019)
  Source of Funding: City of Vienna, City of Vienna Jubilee Fund
  Principal Investigator

Selected publications

1. Onoprienko, A. et al. 2024 ‘Prognostic role of transcription factorARID1Ain patients with endometrial cancer of no specific molecular profile (NSMP) subtype’, International Journal of Gynecologic Cancer, p. ijgc-2023-005111. Available at: https://doi.org/10.1136/ijgc-2023-005111.
2. Bartl, T. et al. 2023 ‘Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer’, International Journal of Gynecologic Cancer, 33(9), pp. 1419–1426. Available at: https://doi.org/10.1136/ijgc-2023-004360.
3. Bartl, T. et al. 2021. ‘Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients’. Cancers, 13(5), p.1076. doi: 10.3390/cancers13051076
4. Kreuzinger, C. et al. 2019 ‘Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer’, Cancer Letters, 459, pp. 1–12. Available at: https://doi.org/10.1016/j.canlet.2019.05.032.
5. Bartl T. et al, 2018. ‘Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer’. International Journal of Gynecologic Cancer,. 2018 Nov;28(9):1664-1671. doi: 10.1097/IGC.0000000000001369.